Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Renal Cell Tumors: Understanding Their Molecular Pathological Epidemiology and the 2016 WHO Classification
Kentaro Inamura
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 10, pp. 2195-2195
Open Access | Times Cited: 144

Showing 1-25 of 144 citing articles:

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update
Börje Ljungberg, Laurence Albigès, Yasmin Abu‐Ghanem, et al.
European Urology (2019) Vol. 75, Iss. 5, pp. 799-810
Open Access | Times Cited: 1199
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update
Börje Ljungberg, Laurence Albigès, Yasmin Abu‐Ghanem, et al.
European Urology (2022) Vol. 82, Iss. 4, pp. 399-410
Open Access | Times Cited: 1087
Microvascular density, macrophages, and mast cells in human clear cell renal carcinoma with and without bevacizumab treatment
Roberto Tamma, Monica Rutigliano, Giuseppe Lucarelli, et al.
Urologic Oncology Seminars and Original Investigations (2019) Vol. 37, Iss. 6, pp. 355.e11-355.e19
Closed Access | Times Cited: 98
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions
Lorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, et al.
OncoImmunology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 71
Imaging Characterization of Renal Masses
Carlos Nicolau, Natalie Antunes, Blanca Paño, et al.
Medicina (2021) Vol. 57, Iss. 1, pp. 51-51
Open Access | Times Cited: 68
MicroRNA‐204‐5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma
Ryoma Kurahashi, Tsuyoshi Kadomatsu, Masaya Baba, et al.
Cancer Science (2019) Vol. 110, Iss. 6, pp. 1897-1908
Open Access | Times Cited: 65
Multiomics characterization and verification of clear cell renal cell carcinoma molecular subtypes to guide precise chemotherapy and immunotherapy
Jialin Meng, Aimin Jiang, Xiaofan Lu, et al.
iMeta (2023) Vol. 2, Iss. 4
Open Access | Times Cited: 21
Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes
Moonsik Kim, Jin Woo Joo, Seok Joo Lee, et al.
Cancers (2020) Vol. 12, Iss. 3, pp. 602-602
Open Access | Times Cited: 40
CircHIPK3 promotes proliferation and metastasis and inhibits apoptosis of renal cancer cells by inhibiting MiR-485-3p
Jinjin Lai, Jun Xin, Changde Fu, et al.
Cancer Cell International (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 40
Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?
Daniele Fanale, Lidia Rita Corsini, R. Scalia, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 170, pp. 103597-103597
Closed Access | Times Cited: 24
The role of miR-155 in urologic malignancies
Maolei Shen, Tao Chen, Xin Li, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116412-116412
Open Access | Times Cited: 6
Cutaneous Metastases: A Review and Diagnostic Approach to Tumors of Unknown Origin
Gabriel Habermehl, Jennifer S. Ko
Archives of Pathology & Laboratory Medicine (2018) Vol. 143, Iss. 8, pp. 943-957
Open Access | Times Cited: 46
The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study
Koji Iinuma, Toyohiro Yamada, Koji Kameyama, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 947-947
Open Access | Times Cited: 12
Clinicopathologic Significance of VHL Gene Alteration in Clear-Cell Renal Cell Carcinoma: An Updated Meta-Analysis and Review
Hyeong Su Kim, Jung Han Kim, Hyun Joo Jang, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 9, pp. 2529-2529
Open Access | Times Cited: 37
Vascular endothelial growth factor and programmed death‐1 pathway inhibitors in renal cell carcinoma
Charlene Mantia, David F. McDermott
Cancer (2019) Vol. 125, Iss. 23, pp. 4148-4157
Open Access | Times Cited: 33
DNA methylation-based classification and identification of renal cell carcinoma prognosis-subgroups
Wenbiao Chen, Zhuang Jia, Peter Wang, et al.
Cancer Cell International (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 30
Overexpression CPT1A reduces lipid accumulation via PPARα/CD36 axis to suppress the cell proliferation in ccRCC
Hui Yang, Hongbo Zhao, Zhongkun Ren, et al.
Acta Biochimica et Biophysica Sinica (2021) Vol. 54, Iss. 2, pp. 220-231
Open Access | Times Cited: 26
Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data
Philippe Barthélémy, N. Costedoat‐Chalumeau, Constance Thibault, et al.
Cancer Treatment Reviews (2021) Vol. 97, pp. 102191-102191
Open Access | Times Cited: 25
ADAM metallopeptidase domain 12 overexpression correlates with prognosis and immune cell infiltration in clear cell renal cell carcinoma
Junjie Gao, Dandan Yang, Haonan Xu, et al.
Bioengineered (2022) Vol. 13, Iss. 2, pp. 2412-2429
Open Access | Times Cited: 18
No Time to Die: How Kidney Cancer Evades Cell Death
Carlo Ganini, Manuela Montanaro, Manuel Scimeca, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 11, pp. 6198-6198
Open Access | Times Cited: 17
The RNA-binding protein KSRP aggravates malignant progression of clear cell renal cell carcinoma through transcriptional inhibition and post-transcriptional destabilization of the NEDD4L ubiquitin ligase
Yi‐Chieh Yang, Yung‐Wei Lin, Wei‐Jiunn Lee, et al.
Journal of Biomedical Science (2023) Vol. 30, Iss. 1
Open Access | Times Cited: 10
MET variants with activating N‐lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation
Célia Guérin, Audrey Vinchent, Marie Fernandes, et al.
Molecular Oncology (2025)
Open Access
Multimodal deep learning with MUF-net for noninvasive WHO/ISUP grading of renal cell carcinoma using CEUS and B-mode ultrasound
Yixin Zhu, Ji Wu, Qiongxian Long, et al.
Frontiers in Physiology (2025) Vol. 16
Open Access
20 Pathology of Metastatic Spinal and Vertebral Column Neoplasms

(2025)
Closed Access
Renal cell cancer treatment: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) surgery-focused consensus update
Stênio de Cássio Zéqui, Ana Galvão, André Costa Matos, et al.
Therapeutic Advances in Urology (2025) Vol. 17
Open Access
Page 1 - Next Page

Scroll to top